


About OMICS Group

OMICS Group International is an amalgamation of [Open Access publications](#) and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology 'Open Access', OMICS Group publishes 500 online open access [scholarly journals](#) in all aspects of Science, Engineering, Management and Technology journals. OMICS Group has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS International also organizes 500 [International conferences](#) annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.

About OMICS International Conferences


OMICS International is a pioneer and leading science event organizer, which publishes around 500 open access journals and conducts over 300 Medical, Clinical, Engineering, Life Sciences, Pharma scientific conferences all over the globe annually with the support of more than 1000 scientific associations and 30,000 editorial board members and 3.5 million followers to its credit.

OMICS International has organized 500 conferences, workshops and national symposiums across the major cities including San Francisco, Las Vegas, San Antonio, Omaha, Orlando, Raleigh, Santa Clara, Chicago, Philadelphia, Baltimore, United Kingdom, Valencia, Dubai, Beijing, Hyderabad, Bengaluru and Mumbai.



HEME BIOLOGY

The Secret Life of Heme in
Regulating Diverse Biological Processes



ZHANG LI
EDITOR


 World Scientific

Heme export

Yeast – Pug1
Mammalian –
FLVCR1, ABCG2

Heme uptake

Yeast - hypoxia inducible heme uptake
C. elegans – HRG4



Worldwide Prevalence of Anemia, by severity





Table 1. Summary of epidemiological studies investigating the association between dietary intake of heme iron and/or red meat with various diseases.

| Disease | Diet Intake | HR/OR/RR (95% CI) Highest vs. Lowest | Reported Association | Number of Participants | Age (Years) | Years of Follow Up | Diet Assessment Method |
|--|-------------------------------|---|---------------------------|---|-------------|--------------------|---|
| Colorectal cancer | Red Meat | HR = 1.24 (1.12–1.36) | + | 567,169 | 50–71 | 8.2 | 124-item FFQ |
| Colon cancer | High heme and low chlorophyll | RR = 1.58 (0.99–2.54) | + | 58,279 Men | 55–69 | 9.3 | 150-item semi quantitative FFQ |
| Colorectal cancer with KRAS mutation | Heme Iron | HR = 1.71 (1.15–2.57) | + | 4026 | 55–69 | 7.3 | 150-item FFQ |
| Esophageal squamous cell carcinoma | Red Meat | HR = 1.79 (1.07–3.01) | + | 494,979 | 50–71 | 10 | 124-item FFQ |
| | Heme Iron | HR = 1.47 (0.99–2.20) | | | | | |
| Esophageal cancer | Red Meat | HR = 1.51 (1.09–2.08) | + | 567,169 | 50–71 | 8.2 | 124-item FFQ |
| | Heme Iron | OR = 3.04 (1.20–7.72) | + | 124 esophageal, 154 stomach cancer and 440 controls | ≥21 | | 100-item Short health habit and history questionnaire |
| Lung cancer | Red Meat | HR _{Men} = 1.11 (0.79–1.56) | No Association | 99,579 | 55–74 | 8 | 124-item FFQ |
| | | HR _{Women} = 1.30 (0.87–1.95) | | | | | |
| | Red Meat | HR = 1.2 (1.10–1.31) | + | 567,169 | | 8.2 | 124-item FFQ |
| | Red Meat | HR _{Men} = 1.22 (1.09–1.38) | + | 278,380 men and 189,596 women | 50–71 | 8 | 124-item FFQ |
| | | HR _{Women} = 1.13 (0.97–1.32) | | | | | |
| | Heme Iron | HR _{Men} = 1.25 (1.07–1.45) | | | | | |
| HR _{Women} = 1.18 (0.99–1.42) | | | | | | | |
| Type 2 Diabetes | Red Meat | RR = 1.44 (0.92–2.24) | moderate, non-significant | 91,246 U.S women | 26–46 | 8 | 133-item semiquantitative FFQ |
| | Red Meat | RR = 1.63 (1.26–2.10) | + | 38,394 Men | 40–75 | 12 | 131-item semiquantitative FFQ |
| | Heme Iron | RR = 1.28 (1.04–1.58) | + | 35,698 postmenopausal women | 55–69 | 11 | 127-item FFQ |
| | Heme Iron | RR = 1.22 (1.14–1.45) | + | 65,024 | 24–59 | 10 | 131-item expanded |

Age-adjusted Cancer Death Rates*, Males by Site, US, 1930-2009




*Per 100,000, age adjusted to the 2000 US standard population.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancer of the liver, lung and bronchus, and colon and rectum are affected by these coding changes.

Source: US Mortality Volumes 1930 to 1959, US Mortality Data 1960 to 2009, National Center for Health Statistics, Centers for Disease Control and Prevention.

©2013, American Cancer Society, Inc., Surveillance Research

Age-adjusted Cancer Death Rates*, Females by Site, US, 1930-2009



*Per 100,000, age adjusted to the 2000 US standard population. †Uterus refers to uterine cervix and uterine corpus combined.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancer of the lung and bronchus, colon and rectum, and ovary are affected by these coding changes.

Source: US Mortality Volumes 1930 to 1959, US Mortality Data 1960 to 2009, National Center for Health Statistics, Centers for Disease Control and Prevention.

©2013, American Cancer Society, Inc., Surveillance Research

Lung Cancer


Non-small cell lung cancer (NSCLC, 85%)

Adenocarcinoma

Squamous cell carcinoma



Large cell carcinomas

Small Cell Lung Cancer (15%)




Normal

NSCLC



HBEC30KT

HCC4017



Proteomic data indicate that hemoproteins are increased in lung cancer cells

A List of Mitochondrial Proteins Upregulated in NSCLC Cells

| <u>Protein ID</u> | <u>Gene Symbol</u> | <u>Description</u> | <u>Fold</u> | <u>p-value</u> |
|-------------------|--------------------|---|-------------|----------------|
| NP_001203 | C1QBP | complement 1 Q subcomponent-binding protein | 1.5 | 3.27E-02 |
| NP_001907 | CYC1 | cytochrome c1, heme protein | 4.3 | 3.61E-02 |
| NP_002147 | HSPD1 | 60 kDa heat shock protein | 3.3 | 5.19E-16 |
| NP_573566 | LRPPRC | leucine-rich PPR motif-containing protein | 3.9 | 4.71E-14 |
| NP_006285 | UQCRB | cytochrome b-c1 complex subunit 7 | 6.1 | 1.68E-02 |


Table 1. Cancer Cells Substantially Increase the Rates of Glucose and Oxygen Consumption*.

| Cell Line | Glu | O ₂ | mtDNA |
|-----------|----------|----------------|-----------|
| HBEC30KT | 10.9±0.6 | 1.07±0.18 | 0.63±0.02 |
| HCC4017 | 15.1±1.0 | 2.47±0.15 | 0.61±0.02 |


*The rates of glucose uptake and oxygen consumption are shown in nmol/min/10⁶ cells, while the mitochondrial DNA level (mtDNA) is shown as the ratio of threshold cycle number of mitochondrial DNA vs. nuclear DNA, measured by real-time PCR.

doi:10.1371/journal.pone.0063402.t001


Heme synthesis is significantly enhanced in cancer cells compared to the normal cells




The level of the rate-limiting heme biosynthetic enzyme ALAS1 is dramatically enhanced in NSCLC cells




and in mouse xenograft tumors




The level of heme-transporting HCP1 is dramatically enhanced in NSCLC cells




and in mouse xenograft tumors




The levels of hemoproteins, such as the oxygen-binding cytoglobin, are dramatically enhanced in NSCLC cells



and in mouse xenograft tumors



hemin std 10-15-2014-9 951 (1.921) Cm (947:980)



Daughter piece
(after lost CH_2COO^- :
 $616-59=557$)

Parent m/z $[\text{M}+\text{H}]^+ (-\text{HCl})$
 $[(651.94-36.5)+1]=616$

TOF MSMS 616.30ES+
8.25e4


Sample 1A

hemin




1:B,415-Oct-2014
sample 1A-10-15-2014-1



TOF MSMS ES+
BPI
2.36e3




Oxygen consumption is intensified in NSCLC cells, and inhibition of heme uptake and biosynthesis suppresses it





Reduction of intracellular heme level inhibits NSCLC cell proliferation and colony formation







Most NSCLC Cell Lines Exhibit Intensified Oxygen Consumption



Cyclopamine Tartrate (CycT), an Inhibitor of Hedgehog Signaling, Strongly Inhibits Lung Cancer Cell Proliferation



Glucose, Glutamine and Cyclopamine Tartrate Strongly Impact the Rate of Oxygen Consumption in NSCLC cells





Cyclopamine Tartrate Causes Mitochondrial Fragmentation



Control

CycT

A549



H1299



Red Meat




Hemoglobin + Myoglobin



Proteolysis

Heme



Increased cellular energy production,
cell proliferation, cell migration and colony
formation

UT Dallas

Jagmohan Hooda

Md M Alam

Sneha Lal

Jonathan Michael Comer

Purna Chaitanya Konduri

Sarada Preeta Kalainayakan

Sagar Sohoni

Tianyuan Wang

Daniela Cadinu

Robert M Henke

Penn State

Bruce and Anne Stanley

Dongxiao Sun

Let Us Meet Again

We welcome you all to our future conferences of
OMICS International

Please Visit:

www.metabolomicsconference.com

www.conferenceseries.com

<http://www.conferenceseries.com/clinical-research-conferences.php>